Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miltirone is a natural lipophilic compound isolated from the root of *Salvia miltiorrhiza* Bunge. It acts as a central benzodiazepine receptor partial agonist and displays diverse pharmacological activities including antiplatelet, antithrombotic, anti-inflammatory, and anticancer effects. Mechanistically, miltirone inhibits platelet aggregation and thrombus formation by suppressing Syk-PLCγ2-PKC/MAPK and PI3K-Akt-GSK3β signaling downstream of the glycoprotein VI pathway, and Src/FAK signaling in integrin αIIbβ3-mediated platelet "outside-in" signaling[1]. In cancer models, miltirone induces apoptosis in various cell types, enhances chemosensitivity to agents such as cisplatin, and downregulates the PI3K/Akt/mTOR pathway, as well as affecting other pathways such as MEK/ERK1/2 and mitochondrial ROS generation[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miltirone.